



Mouse Anti-Durvalumab monoclonal antibody, clone 26E7 (CABT-ZB202)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB202 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab.
Specificity	The product is specific for Durvalumab.
Target	Durvalumab
Immunogen	Durvalumab
Isotype	IgG2a, κ
Source/Host	Mouse
Clone	26E7
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded. Recommended Working Concentration: 0.01-0.1 µg/ml
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.
Size	40 µg
Buffer	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.

Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1k monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
Keywords	Mouse monoclonal antibody to Imfinzi; Durvalumab; Imfinzi; MEDI-4736

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Imfinzi; Durvalumab; Imfinzi; MEDI-4736
-----------------	--